

## Glucocorticoids reprogram $\beta$ -cell signaling to preserve insulin secretion

Fine, Nicholas; Doig, Craig; Elhassan, Yasir; Vierra, Nicholas; Marchetti, Piero; Bugliani, Marco; Nano, Rita; Piemonti, Lorenzo; Rutter, Guy; Jacobson, David A; Lavery, Gareth; Hodson, David

DOI:

[10.2337/db16-1356](https://doi.org/10.2337/db16-1356)

License:

None: All rights reserved

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Fine, N, Doig, C, Elhassan, Y, Vierra, N, Marchetti, P, Bugliani, M, Nano, R, Piemonti, L, Rutter, G, Jacobson, DA, Lavery, G & Hodson, D 2018, 'Glucocorticoids reprogram  $\beta$ -cell signaling to preserve insulin secretion', *Diabetes*, vol. 67, no. 2, pp. 278-290. <https://doi.org/10.2337/db16-1356>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

Accepted for publication in *Diabetes*, Nicholas H.F. Fine, Craig L. Doig, Yasir S. Elhassan, Nicholas C. Vierra, Piero Marchetti, Marco Bugliani, Rita Nano, Lorenzo Piemonti, Guy A. Rutter, David A. Jacobson, Gareth G. Lavery and David J. Hodson, *Diabetes* 2017 Dec; db161356. <https://doi.org/10.2337/db16-1356>

© 2017 by the American Diabetes Association. <http://www.diabetesjournals.org/content/license>

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.



## Glucocorticoids reprogram beta cell signaling to preserve insulin secretion

Journal:	<i>Diabetes</i>
Manuscript ID	DB16-1356.R4
Manuscript Type:	Original Article: Islet Studies
Date Submitted by the Author:	27-Oct-2017
Complete List of Authors:	<p>Fine, Nicholas; University of Birmingham, Endocrinology, Diabetes and Metabolism</p> <p>Doig, Craig; University of Birmingham, Endocrinology, Diabetes and Metabolism</p> <p>Elhassan, Yasir; University of Birmingham, Endocrinology, Diabetes and Metabolism</p> <p>Vierra, Nicholas; Vanderbilt University, Molecular Physiology</p> <p>Marchetti, Piero; Metabolic Unit, Endocrinology &amp; Metabolism</p> <p>Bugliani, Marco; University of Pisa, Dept. Clinical and Experimental Medicine</p> <p>Nano, Rita; IRCCS San Raffaele Scientific Institute, San Raffaele Diabetes Research Institute</p> <p>Piemonti, Lorenzo; IRCCS San Raffaele Scientific Institute, San Raffaele Diabetes Research Institute</p> <p>Rutter, Guy; Imperial College London, Cell Biology, Division of Medicine;</p> <p>Jacobson, David; Vanderbilt University, Molecular Physiology</p> <p>Lavery, Gareth; University of Birmingham, Division of Medicine</p> <p>Hodson, David; University of Birmingham, Institute of Metabolism and Systems Research</p>

SCHOLARONE™  
Manuscripts

**Glucocorticoids reprogram beta cell signaling to preserve insulin secretion**

Nicholas H.F. Fine<sup>1,2</sup>, Craig L. Doig<sup>1,2</sup>, Yasir S. Elhassan<sup>1,2</sup>, Nicholas C. Vierra<sup>3</sup>, Piero Marchetti<sup>4</sup>, Marco Bugliani<sup>4</sup>, Rita Nano<sup>5</sup>, Lorenzo Piemonti<sup>5</sup>, Guy A. Rutter<sup>6</sup>, David A. Jacobson<sup>3</sup>, Gareth G. Lavery<sup>1,2</sup> and David J. Hodson<sup>1,2,7\*</sup>

<sup>1</sup>Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Edgbaston, B15 2TT, UK. <sup>2</sup>Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, B15 2TH, UK. <sup>3</sup>Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN. <sup>4</sup>Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. <sup>5</sup>Diabetes Research Institute, San Raffaele Scientific Institute, Milan, Italy. <sup>6</sup>Section of Cell Biology and Functional Genomics, Department of Medicine, Imperial College London, W12 0NN, UK. <sup>7</sup>COMPARE University of Birmingham and University of Nottingham Midlands, UK.

Running title: glucocorticoids reprogram beta cell signaling to preserve insulin secretion

Key words: islet, insulin, incretin, steroid, glucocorticoid, 11 $\beta$ -hydroxysteroid dehydrogenase type 1, adenylate cyclase, cAMP

Word count (main body): 4,000

\*Correspondence to:  
David J. Hodson,  
Office 227, IBR Tower,  
Institute of Metabolism and Systems Research,  
University of Birmingham,  
Edgbaston, B15 2TT, UK  
+44(0)121 414 6896  
[d.hodson@bham.ac.uk](mailto:d.hodson@bham.ac.uk)

## 1 ABSTRACT

2 Excessive glucocorticoid exposure has been shown to be deleterious for pancreatic beta cell  
3 function and insulin release. However, glucocorticoids at physiological levels are essential  
4 for many homeostatic processes, including glycemic control. Here, we show that  
5 corticosterone and cortisol and their less active precursors, 11-dehydrocorticosterone (11-  
6 DHC) and cortisone, suppress voltage-dependent  $\text{Ca}^{2+}$  channel function and  $\text{Ca}^{2+}$  fluxes in  
7 rodent as well as human beta cells. However, insulin secretion, maximal ATP/ADP responses  
8 to glucose and beta cell identity were all unaffected. Further examination revealed the  
9 upregulation of parallel amplifying cAMP signals, and an increase in the number of  
10 membrane-docked insulin secretory granules. Effects of 11-DHC could be prevented by  
11 lipotoxicity and were associated with paracrine regulation of glucocorticoid activity, since  
12 global deletion of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 normalized  $\text{Ca}^{2+}$  and cAMP  
13 responses. Thus, we have identified an enzymatically-amplified feedback loop whereby  
14 glucocorticoids boost cAMP to maintain insulin secretion in the face of perturbed ionic  
15 signals. Failure of this protective mechanism may contribute to diabetes in states of  
16 glucocorticoid excess such as Cushing's syndrome, which are associated with frank  
17 dyslipidemia.

18

1 INTRODUCTION

2 Circulating glucocorticoids exert potent metabolic effects including lipolysis, hepatic  
3 gluconeogenesis, amino acid mobilization and reduced skeletal muscle glucose uptake (1).  
4 This is facilitated by the enzyme 11 $\beta$ -hydroxysteroid dehydrogenase type 1 (HSD11B1),  
5 which (re)activates glucocorticoid in a tissue-specific manner to determine bioavailability (2).  
6 As such, states of excess glucocorticoids (*e.g.* Cushing’s syndrome) are pro-diabetic, since  
7 they cause profound glucose intolerance and insulin resistance.

8 While systemic administration of glucocorticoids induces a compensatory increase in  
9 beta cell mass, and eventually insulin secretory failure due to insulin resistance (3), effects  
10 directly on beta cell function are less well understood. Suggesting an important link between  
11 glucocorticoids and insulin release, beta cell-specific glucocorticoid receptor (GR)  
12 overexpression reduces glucose tolerance (4). However, *in vitro* studies using isolated islets  
13 have shown inhibitory or no effect of glucocorticoids on glucose-stimulated insulin secretion  
14 depending on the steroid potency, concentration and treatment duration (5-9). By contrast,  
15 HSD11B1 increases ligand availability at the GR by converting less active to more active  
16 glucocorticoid (11-dehydrocorticosterone (11-DHC) -> corticosterone in rodents; cortisone -  
17 > cortisol in man), impairing beta cell function in islets both *in vitro* and *in vivo* (6; 10; 11).  
18 Whereas 11-DHC has consistently been shown to impair beta cell function in islets from  
19 obese animals, conflicting reports exist regarding its effects on normal islets (7; 10).

20 More generally, the signaling components targeted by glucocorticoids are not well  
21 defined. While exogenous application of glucocorticoid subtly decreases insulin release, and  
22 nicotinamide adenine dinucleotide phosphate, 3',5'-cyclic adenosine monophosphate (cAMP)  
23 and inositol phosphate production (5), these studies were performed using high dose  
24 dexamethasone (25x relative potency compared to cortisol). Conversely, administration of the  
25 same glucocorticoid in drinking water augments insulin release by increasing the number of

docked exocytotic vesicles, as well as beta cell mitochondrial potential/metabolism (12). However, indirect effects of insulin resistance cannot be excluded, as studies in high fat diet-fed mice have shown that compensatory beta cell responses, including proliferation, occur within a few days (13). Lastly, glucocorticoid administration or GR deletion in the early neonatal period alters beta cell development, leading to reductions in the expression of key maturity markers including Pdx1, Nkx6.1 and Pax6 (14; 15). Whether this is also seen in adult islets, as may occur during diabetes (16), is unknown.

In the present study, we therefore sought to investigate the mechanisms by which the endogenous glucocorticoids corticosterone and cortisol affect beta cell function. Using *in situ* imaging approaches together with biosensors, we reveal that glucocorticoids perturb cytosolic  $\text{Ca}^{2+}$  concentration through effects on voltage-dependent  $\text{Ca}^{2+}$  channel (VDCC) function, without altering beta cell maturity, glucose-induced changes in ATP/ADP ratio or incretin responsiveness. This however does reduce insulin secretion, since glucocorticoids upregulate parallel cAMP signaling pathways. The less active glucocorticoids 11-DHC and cortisone showed identical effects, which could be reversed in mouse following global deletion of *Hsd11b1*. Thus, a steroid-regulated feedback loop, encompassing an enzymatic amplification step, maintains normal insulin secretory output in the face of impaired beta cell ionic fluxes.

1     **MATERIALS AND METHODS**

2     **Animals**

3     CD1 mice (8-12 weeks, males) were used as wild-type tissue donors. *Hsd11b1*<sup>-/-</sup> mice were  
4     generated as described (17). Studies were regulated by the Animals (Scientific Procedures)  
5     Act 1986 of the United Kingdom, and approval granted by the University of Birmingham’s  
6     Animal Welfare and Ethical Review Body.

7     **Islet isolation**

8     Islets were isolated using collagenase digestion and cultured in RPMI supplemented with  
9     10% fetal calf serum, 100 U/mL penicillin and 100 µg/mL streptomycin. Vehicle (ethanol  
10    0.2%), 11-DHC (20/200 nM) or corticosterone (20 nM) (*i.e.* within the circulating free  
11    glucocorticoid range) were applied for 48 hrs. BSA-conjugated palmitate was applied at 0.5  
12    mM.

13    **Human islet culture**

14    Islets were obtained from isolation centers at Alberta (IsletCore) (18), Pisa and Milan, with  
15    local and national ethical permissions. Islets were cultured in RPMI containing 10% fetal  
16    calf serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml fungizone,  
17    supplemented with 5.5 mM D-glucose, and treated with either vehicle (ethanol 0.2%),  
18    cortisone (200 nM) or cortisol (20 nM) for 48 hrs. See Supplemental Table 1 for donor  
19    characteristics. Studies were approved by the National Research Ethics Committee (NRES),  
20    REC reference 16/NE/0107.

21    **Calcium, ATP/ADP and cAMP imaging**

22    Islets were loaded with 10 µM Fluo8 AM for 45 mins at 37 °C before washing and  
23    incubation in buffer for a further 30 min to allow cleavage by intracellular esterase. Imaging  
24    was conducted using either: 1) a Crest X-Light spinning disk and 10 x/0.4 NA objective; or  
25    2) a Zeiss LSM780 and 10 x/0.45 NA objective. For the Crest system, excitation was

delivered at  $\lambda = 458\text{--}482$  nm (400 ms exposure; 0.33 Hz) and emitted signals detected at  $\lambda = 500\text{--}550$  nm using an EMCCD. For the Zeiss system, excitation was delivered at  $\lambda = 488$  nm, and emitted signals detected at  $\lambda = 499\text{--}578$  nm using a PMT. Fura2 was loaded as for Fluo8 and imaging performed using LEDs (excitation  $\lambda = 340/385$  nm; emission  $\lambda = 470\text{--}550$  nm).

ATP/ADP ratios and cAMP responses were measured using adenovirus harboring either Perceval (excitation/emission as for Fluo8) or the FRET probe Epac2-camps (excitation  $\lambda = 430\text{--}450$  nm; emission  $\lambda = 460\text{--}500$  nm and  $520\text{--}550$  nm) (19; 20). For Perceval, glucose was increased from 3–11 mM, which leads to plateau responses (21). An effect of glucocorticoid on Epac2-camps expression was unlikely, since single and dual channel fluorescence under maximal stimulation was similar for all treatments (Supplemental Table 2). In all cases, HEPES-bicarbonate buffer was used, containing (in mM): 120 NaCl, 4.8 KCl, 24 NaHCO<sub>3</sub>, 0.5 Na<sub>2</sub>HPO<sub>4</sub>, 5 HEPES, 2.5 CaCl<sub>2</sub>, 1.2 MgCl<sub>2</sub>, 3–17 D-glucose. Ca<sup>2+</sup>, cAMP and ATP/ADP traces were normalized as  $F/F_{\min}$ , where  $F$  = fluorescence at any given time point and  $F_{\min}$  = minimum fluorescence during the recording (*i.e.* under basal conditions).

## Electrophysiology

VDCC currents were recorded from dispersed mouse beta cells, as previously described (22). Patch electrodes were pulled to a resistance of 3–4 M $\Omega$  then filled with an intracellular solution containing (in mM): 125 CsCl, 10 tetraethylammonium Cl (TEA), 1 MgCl<sub>2</sub>, 5 EGTA, 10 HEPES, 3 MgATP, pH 7.22 with CsOH. Cells were patched in HEPES-buffered solution + 17 mM glucose. Upon obtaining the whole-cell configuration with a seal resistance > 1 G $\Omega$ , the bath solution was exchanged for a modified HEPES-buffered solution containing (in mM): 62 NaCl, 20 TEA, 30 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 5 CsCl, 10 HEPES, 17 glucose, 0.1 tolbutamide, pH 7.35 with NaOH. Beta cells were perfused for 3 mins with this solution prior to initiating the VDCC recording protocol. Voltage steps of 10 mV were applied from a



1 holding potential of -80 mV; linear leak currents were subtracted online using a P/4 protocol.  
2 Data were analyzed using Clampfit (Molecular Devices).

### 3 **Immunohistochemistry and super-resolution imaging**

4 Islets were fixed overnight at 4°C in 4% paraformaldehyde before immunostaining using  
5 rabbit monoclonal anti-insulin (Cell Signaling Technology; 1:400) and goat anti-rabbit  
6 Alexa568 (1:1000). Super-resolution imaging was performed using a VisiTech iSIM and a  
7 100x/1.49 NA objective. Excitation was delivered using a  $\lambda = 561$  nm and emitted signals  
8 captured at  $\lambda = 633$ -647 nm using a sCMOS. Image stacks were cropped to include only the  
9 near-membrane regions and exclude out-of-focus signal, converted to 8-bit grayscale, before  
10 obtaining the maximum intensity projection. Auto-thresholding was performed in Fiji (NIH)  
11 to produce a binary snapshot from which the area occupied by insulin granules could be  
12 quantified as a unitary ratio (V/v) *versus* the total membrane area using the analyze particle  
13 plugin, as previously described (20).

### 14 **Real-time PCR**

15 Relative mRNA abundance was determined using SYBR Green chemistry and fold-change in  
16 mRNA expression calculated compared to *Actb* using the  $2^{-\Delta\Delta C_t}$  method (see Supplemental  
17 Table 3 for primer sequences). *Hsd11b1* mRNA abundance was determined using TaqMan  
18 assays for mouse (Cat. # 4331182) and human (Cat. # 4331182) tissue, *Hsd11b1* expression  
19 calculated using  $2^{-\Delta C_t} \times 1000$ , and transformed values presented as arbitrary units.

### 20 **Measurements of insulin secretion and ATP in isolated islets**

21 Batches of eight islets were placed in low-bind Eppendorf tubes, incubated for 30 mins at 37  
22 °C in HEPES-bicarbonate buffer containing 3 mM glucose, before addition of either 3 mM  
23 glucose, 17 mM glucose or 17 mM glucose + 10 mM KCl for a further 30 mins and  
24 collection of supernatant. Total insulin was extracted into acid-ethanol. Insulin concentration  
25 was determined using a Homogeneous Time Resolved Fluorescence (HTRF)-based assay

1 (Cisbio) according to the manufacturer's instructions. Total ATP at 3 and 17 mM glucose  
2 was measured in batches of 25 islets using a luciferase-based assay (Invitrogen), and values  
3 normalized to total protein.

#### 4 **Statistical analyses**

5 Pairwise comparisons were performed using paired or unpaired Student's t-test. Interactions  
6 between multiple treatments were determined using one-way ANOVA (adjusted for repeated  
7 measures as necessary), followed by Bonferonni's or Tukey's post hoc test. Analyses were  
8 conducted using Graphpad Prism and IgorPro.

9

## 1 RESULTS

### 2 Glucocorticoids alter ionic but not metabolic fluxes

3 Fluo8-loaded beta cells residing within intact islets of Langerhans were subjected to  
 4 multicellular  $\text{Ca}^{2+}$ -imaging approaches (23). Individual beta cells responded to elevated  
 5 glucose (3 mM  $\rightarrow$  17 mM) with large increases in cytosolic  $\text{Ca}^{2+}$  levels (Fig. 1A and B).  
 6 Whereas 11-DHC 20 nM was without effect, higher (200 nM) concentrations suppressed the  
 7 amplitude and area-under-the-curve (AUC) of  $\text{Ca}^{2+}$  rises in response to glucose and glucose +  
 8 10 mM KCl by ~30% (Fig. 1A-E) (Supplemental Fig. 1A and B) (Supplemental Fig. 2A-C),  
 9 and this reached ~50% in the presence of corticosterone 20 nM. Results were confirmed  
 10 using the ratiometric  $\text{Ca}^{2+}$  indicator Fura2, excluding a major contribution of basal  $\text{Ca}^{2+}$   
 11 levels to the magnitude changes detected here (Supplemental Fig. 2A-C). No effect of  
 12 glucocorticoid on the time to onset of  $\text{Ca}^{2+}$  rises was detected (lag period  $\pm$  SD =  $22.5 \pm 7.7$   
 13 *versus*  $26.3 \pm 9.7$  *versus*  $24.0 \pm 6.2$  s for control, 11-DHC and corticosterone, respectively;  
 14 non-significant, one-way ANOVA). The peak  $\text{Ca}^{2+}$  response to KCl depolarization in low (3  
 15 mM) glucose was unaffected by 11-DHC and significantly increased by corticosterone  
 16 (Supplemental Fig. 2D and E), although both glucocorticoids reduced  $\text{Ca}^{2+}$  amplitude when  
 17 KCl concentration was increased from 10 to 30 mM (Supplemental Fig. 2F and G) (24).  
 18 While both 11-DHC and corticosterone led to more sustained  $\text{Ca}^{2+}$  influx in response to 3  
 19 mM glucose + 10 mM KCl (Supplemental Fig. 2E), this was not the case with 30 mM KCl  
 20 (Supplemental Fig. 2G). An effect of treatment on basal  $\text{Ca}^{2+}$  levels at 3 mM glucose was  
 21 unlikely, since the Fura2 340/385 ratio was not significantly affected by 11-DHC or  
 22 corticosterone (Supplemental Fig. 2H).

23 Supporting an action on later steps in ionic flux generation, 11-DHC and  
 24 corticosterone reduced  $\text{Ca}^{2+}$  oscillation frequency at moderately (11 mM) elevated glucose  
 25 concentration (Fig. 1F and G). Glucocorticoids (cortisone and cortisol) also suppressed  $\text{Ca}^{2+}$

responses to glucose and glucose + 10 mM KCl in human islets (Fig. 1H-J), without significantly altering basal  $\text{Ca}^{2+}$  concentration (Supplemental Table 4). The reported glucocorticoid actions were specific to glucose, as both 11-DHC and corticosterone were unable to influence  $\text{Ca}^{2+}$  responses to exendin-4 in mouse islets in terms of oscillation frequency and AUC (Fig. 1K-M), these parameters being the primary drivers of incretin-stimulated  $\text{Ca}^{2+}$  fluxes in this species (23).

### **Beta cells remain differentiated in the presence of glucocorticoids**

Immature or de-differentiated beta cells fail to respond properly to glucose, a defect that can partly be explained by lowered transcription factor expression, and impairments in metabolism and  $\text{Ca}^{2+}$  flux generation (25). This was unlikely to be the case here, however, as 11-DHC and corticosterone did not significantly affect mRNA abundance of the key beta cell maturity markers *Pdx1* (Fig. 2A-C) and *Nkx6.1* (Fig. 2D-F). Moreover, maximal ATP/ADP increases in response to glucose, measured using the biosensor Perceval (26), were not significantly different (Fig. 2G and H). 11-DHC and corticosterone did not affect the time to onset (Supplemental Fig. 3A) or the amplitude (Supplemental Fig. 3B) of the initial, transient decrease in ATP/ADP. No significant effects of glucocorticoid on basal or glucose-stimulated ATP levels were detected using luciferase-based assays (Supplemental Fig. 4). Patch-clamp electrophysiology revealed abnormal VDCC function in the presence of glucocorticoids, with voltage-current (I-V) curves showing a marked reduction in  $\text{Ca}^{2+}$  conductance (Fig. 2I and J). Suggestive of changes in VDCC function rather than expression, transcript levels of the major alpha and beta subunits *Cacna1c* (Fig. 2K and L), *Cacnb2* (Fig. 2M and N) and *Cacna1d* (Fig. 2O and P) were not significantly altered.

### **Glucocorticoids do not affect insulin secretory responses**

In response to glucose, increases in ATP/ADP ratios lead to closure of  $\text{K}_{\text{ATP}}$ -channels, opening of VDCCs and  $\text{Ca}^{2+}$ -dependent insulin secretion (27). Thus, perturbed cytosolic  $\text{Ca}^{2+}$

1 fluxes/levels generally translate to reductions in insulin secretory output (27). However,  
2 glucose and glucose + KCl-stimulated insulin release were not significantly different  
3 following 48 hr exposure of islets to 11-DHC or corticosterone (Fig. 3A). This was not due to  
4 an increase in insulin expression, since *Ins1* mRNA levels were similar in the presence of  
5 both glucocorticoids (Fig. 3B-D). Likewise, total insulin content was not significantly  
6 different between treatments under all stimulation conditions examined (Fig. 3E). Insulin  
7 secretion was also unaffected by cortisone and cortisol treatment in primary human islets  
8 (Fig. 3F and G) (Supplemental Table 1).

### 9 **cAMP signals are upregulated by glucocorticoids**

10 Granule release competency can be increased by signals including cAMP, which acts directly  
11 upon protein kinase A (PKA) and exchange protein directly activated by cAMP 2 (Epac2)  
12 (28). Using the FRET probe Epac2-camps to dynamically report cytosolic cAMP (20),  
13 glucose induced a robust increase in levels of the nucleotide (Fig. 4A). Both 11-DHC and  
14 corticosterone upregulated cAMP responses to glucose by ~1.5-fold (Fig. 4A-C). This  
15 appeared necessary for maintenance of secretory output, since chemical inhibition of PKA  
16 significantly reduced glucose-stimulated insulin release in 11-DHC-treated islets (Fig. 4D).  
17 Indeed, more granules were present at the membrane in glucocorticoid-treated islets, revealed  
18 using super-resolution structured illumination microscopy (SIM) (Fig. 4E and F). Similar  
19 results were seen in human islets, with cortisone and cortisol both augmenting cAMP  
20 responses to glucose (Fig. 4G and H). As for  $\text{Ca}^{2+}$ , the actions of glucocorticoid were  
21 glucose-specific, as neither 11-DHC nor corticosterone altered cAMP responses to exendin-4  
22 (Fig. 4I and J). Supporting a central role for adenylate cyclase (*Adcy*) in this effect,  
23 expression of *Adcy1* was increased by both glucocorticoids (Fig. 4K and L), and induction of  
24 lipotoxicity with palmitate- shown previously to lower *Adcy9* mRNA (29)- prevented  
25 glucocorticoid from augmenting cAMP responses to glucose (Fig. 4M and N).

### 1 ***Hsd11b1* is expressed in islets of Langerhans**

2 HSD11B1 is responsible for catalyzing the conversion of 11-DHC to corticosterone and is an  
3 important mechanism that determines local glucocorticoid activity (30). Expression of  
4 *Hsd11b1* in islets has previously been shown to be sufficient for 11-DHC → corticosterone  
5 conversion (7). We therefore repeated studies in islets obtained from mice globally lacking  
6 one (*Hsd11b1*<sup>+/-</sup>) or both (*Hsd11b1*<sup>-/-</sup>) alleles of *Hsd11b1*. While *Hsd11b1* mRNA levels were  
7 low in mouse islets compared to liver and muscle, it was still detectable ( $\Delta\text{Ct} = 7.33 \pm 1.80$ )  
8 (Supplemental Fig. 5A). Moreover, *Hsd11b1* mRNA abundance was 55-75% lower in islets  
9 from animals expressing a single copy of *Hsd11b1* and undetectable in those deleted for both  
10 alleles (Supplemental Fig. 5B), as assessed using specific TaqMan assays. Quantification of  
11 *HSD11B1* mRNA revealed similar levels in human and mouse islets, with expression an  
12 order of magnitude lower than in human subcutaneous and omental adipose tissue  
13 (Supplemental Fig. 5C), a major site of enzyme activity and steroid reactivation (31).

### 14 ***Hsd11b1* deletion reverses the effects of glucocorticoids on beta cell $\text{Ca}^{2+}$ and cAMP** 15 **signaling**

16 As expected, both 11-DHC and corticosterone impaired cytosolic  $\text{Ca}^{2+}$  fluxes in beta cells  
17 residing within islets from *Hsd11b1*<sup>+/-</sup> animals (Fig. 5A-D) (Supplemental Fig. 6A and B).  
18 However, deletion of *Hsd11b1*<sup>-/-</sup> throughout the islet reversed these effects, with 11-DHC and  
19 corticosterone no longer able to suppress  $\text{Ca}^{2+}$  rises in response to glucose- or glucose + KCl  
20 (Fig. 5E-H) (Supplemental Fig. 6C and D). This suggests that local regulation of  
21 glucocorticoid activity in the islet may mediate the effects of 11-DHC and corticosterone on  
22 beta cell  $\text{Ca}^{2+}$  fluxes. 11-DHC was able to significantly elevate cAMP responses to glucose in  
23 *Hsd11b1*<sup>+/-</sup> (Fig. 6A-D) (Supplemental Fig. 7A), but not *Hsd11b1*<sup>-/-</sup> islets (Fig. 6E-H)  
24 (Supplemental Fig. 7B). However, corticosterone still improved cAMP responses to glucose,  
25 even following deletion of *Hsd11b1* (Fig. 6A-H) (Supplemental Fig. 7A and B). Glucose-

1 stimulated insulin secretion was significantly higher in corticosterone- *versus* control- or 11-  
2 DHC-treated *Hsd11b1*<sup>-/-</sup> islets (Fig. 6I), consistent with the Ca<sup>2+</sup> and cAMP results. Similarly,  
3 QRT-PCR analyses revealed upregulation of *Adcy1* expression by corticosterone, but not **by**  
4 11-DHC, in *Hsd11b1*<sup>-/-</sup> islets (Fig. 6J and K). Ca<sup>2+</sup> responses to glucose, glucose + KCl and  
5 KCl were not significantly decreased by 11-DHC (Fig. 7A-D) (Fig. 7E and F) (Supplemental  
6 Fig. 8A and B) in islets pre-treated with RU486. Similarly, corticosterone was unable to  
7 impair Ca<sup>2+</sup> responses to glucose and KCl in RU486-treated islets (Fig. 7E) (Supplemental  
8 Fig. 8C and D), although Ca<sup>2+</sup> responses to glucose + KCl were unaffected (Fig. 7F). Thus,  
9 the inhibitory actions of the glucocorticoids are partly mediated by the GR.

10

## 1 DISCUSSION

2 We show here that corticosterone and cortisol and their less active precursors, 11-DHC and  
3 cortisone, impair glucose-, glucose + KCl- and KCl-stimulated ionic fluxes in rodent and  
4 human beta cells. However, insulin secretory output is likely preserved because both  
5 glucocorticoids upregulate cAMP signals to increase insulin granule number at the  
6 membrane. Invoking a critical role for glucocorticoid interconversion, the effects of 11-DHC  
7 could be prevented following islet-wide deletion of HSD11B1. Thus, an enzyme-assisted  
8 steroid-regulated feedback loop maintains insulin secretion in the face of altered beta cell  
9 ionic signaling (Fig. 8).

10 Both corticosterone and 11-DHC have previously been shown to exert inhibitory  
11 effects on insulin release (6; 7; 10; 11). However, these studies either used islets from *ob/ob*  
12 mice that display highly upregulated *Hsd11b1* expression (6; 10), or incubated wild-type  
13 islets with glucocorticoid for only two hours (7; 11), which is unlikely to fully compensate  
14 the loss of adrenal input that occurs following islet isolation. Likewise, studies in which  
15 glucocorticoids are administered in the drinking water are confounded by insulin resistance  
16 and compensatory islet expansion (12). Thus, the effects observed in the present study more  
17 likely reflect the cellular/molecular actions of circulating glucocorticoids under normal  
18 conditions.

19 Cytosolic  $\text{Ca}^{2+}$  responses to glucose were impaired in the presence of either 11-DHC  
20 or corticosterone. This was unlikely due to defects in metabolism and  $\text{K}_{\text{ATP}}$ -channel function,  
21 since glucose-induced ATP/ADP maximal rises were unaffected. However, KCl- and KCl +  
22 glucose-induced  $\text{Ca}^{2+}$  influx, as well as VDCC conductance, were markedly suppressed,  
23 although QRT-PCR analyses of expression levels of the key L-type VDCC subunits showed  
24 no differences. Paradoxically, glucocorticoid improved the sustained  $\text{Ca}^{2+}$  responses to 3 mM  
25 glucose + 10 mM KCl. While this may reflect basal cAMP generation due to upregulated



*Adcy1*, it should be noted that VDCCs do not open fully under these conditions (Supplemental Table 5), meaning that true defects in their activity are likely to be missed. Indeed, glucocorticoids may induce changes that only restrict  $\text{Ca}^{2+}$  entry when VDCC open probability increases to support insulin secretion (i.e. 17 mM glucose and/or 30 mM KCl).

$\text{Ca}^{2+}$  oscillation frequency was also affected, suggesting that glucocorticoids may conceivably target more distal steps in  $\text{Ca}^{2+}$  flux generation, such as intracellular stores (e.g. by depleting them through cAMP-sensitization of  $\text{IP}_3$  receptors (32)), upregulate ion channels involved in voltage-inactivation (i.e. large-conductance  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  channels (33)), or alter glucose-regulated inputs other than cAMP (34). These effects are presumably specific to glucose-stimulated  $\text{Ca}^{2+}$  rises, as responses to the incretin-mimetic exendin 4 remained unchanged by glucocorticoid exposure, possibly due to PKA-mediated rescue of VDCC function or organellar  $\text{Ca}^{2+}$  release (35).

Recent RNASeq analyses of purified mouse beta cells have shown that *Hsd11b1* mRNA levels are unusually low in these and other islet neuroendocrine cells (i.e. it is an islet “disallowed” gene) (36). Likewise, *HSD11B1* mRNA levels were low in human beta and alpha cells (37). These findings contrast with reports that protein expression co-localizes with glucagon or insulin in rodent islets depending on the antibody used (7; 38). The reasons for these discrepancies are unclear, but in the present study specific TaqMan assays showed consistently detectable mRNA levels in both rodent and human islets. Moreover, 11-DHC effects could be prevented in global *Hsd11b1*<sup>-/-</sup> islets in which mRNA was largely absent, and *HSD11B1* expression in human islets was an order of magnitude lower than in adipose tissue, a major site for steroid reactivation after the liver (31). Thus, 11-DHC likely affects beta cell function in a paracrine manner, possibly through the actions of HSD11B1 in non-endocrine islet cell types (e.g. endothelial cells where expression levels are higher (37)). This may form the basis of an adaptive mechanism to prevent the build-up of high local

1 corticosterone/cortisol concentrations. Together, these data highlight the importance of the  
2 islet context for the regulation of insulin secretion, and underline the requirement to consider  
3 cell-cell cross-talk when assessing the functional consequences of beta cell gene  
4 disallowance.

5 Global deletion of *Hsd11b1* prevented the effects of 11-DHC on ionic and cAMP  
6 fluxes, as expected, suggesting that local regulation of glucocorticoid activity is important for  
7 beta cell function. However, corticosterone was unable to impair  $\text{Ca}^{2+}$  responses in *Hsd11b1*<sup>-/-</sup>  
8 islets, whereas potentiation of cAMP remained intact. Together, these observations raise the  
9 possibility that corticosterone may undergo substantial oxidation to 11-DHC *via* HSD11B2  
10 (37), with local concentrations dropping below the threshold for suppression of  $\text{Ca}^{2+}$  but not  
11 cAMP following *Hsd11b1* knockout. While previous studies have shown that a single  
12 *Hsd11b1* allele is sufficient for full enzymatic activity (39), further studies are required to  
13 determine whether this is also the case in islets.

14 Consistent with upregulated cAMP signaling, an increase in the number of sub-  
15 membrane insulin granules was observed in glucocorticoid-treated islets. cAMP has been  
16 shown to recruit non-docked insulin granules to the membrane, as well as increase the size of  
17 the readily-releasable granule pool *via* Epac2 and PKA (40; 41), and this may account for the  
18 intact secretory responses to glucose and KCl. The exact mechanisms by which 11-DHC and  
19 corticosterone boost cAMP signaling are unknown, but likely involve specific adenylate  
20 cyclases, since *Adcy1* gene expression was increased in 11-DHC- and corticosterone-treated  
21 islets compared to controls. Moreover, palmitate, which downregulates *Adcy9* and impairs  
22 cAMP responses to glucose (29), prevented 11-DHC from increasing cAMP levels. While  
23 *Adcy9* mRNA expression was not significantly affected by glucocorticoid, other mechanisms  
24 can account for cAMP generation, including organization of the enzyme into microdomains  
25 (42). Pertinently, *Adcy1* and *Adcy9* knockdown have been shown to reduce glucose-

1 stimulated cAMP rises and insulin secretion in beta cells (29; 43). Further studies are thus  
2 warranted in glucocorticoid-treated *Adcy1*- and *Adcy9*-null islets. Upregulated cAMP  
3 signaling may represent a protective mechanism that is disrupted by free fatty acids to induce  
4 beta cell failure/decompensation in the face of excess glucocorticoid. Of note, endogenous  
5 elevation of glucocorticoids leads to dyslipidemia due to lipolysis, *de novo* fatty acid  
6 production/turnover and hepatic fat accumulation (44).

7       It has previously been shown in mouse islets that cAMP responses to glucose are  
8 oscillatory (29), albeit noisier than those in MIN6/INS-1E cells (45). However, the latter  
9 studies used TIRF microscopy to study sub-membraned cAMP responses, whose changes  
10 may be larger and more dynamic than those recorded throughout the cytosol (46). Similar  
11 studies using epifluorescence techniques show non-oscillatory cAMP increases in response to  
12 high glucose concentrations (47). Thus, further studies are required to investigate the impact  
13 of glucocorticoids on cAMP oscillations, which were not detectable at the axial resolutions  
14 employed here. While ATP/ADP responses were oscillatory in single islets, a transient dip  
15 was present following introduction of high glucose. This has also been seen in previous  
16 studies (19) and may reflect net ATP consumption secondary to  $\text{Ca}^{2+}$  transporter activity (48),  
17 glucokinase activity (49) and the initial steps of exocytosis (50), or an uncoupling effect of  
18 highly elevated  $\text{Ca}^{2+}$  levels on mitochondrial function (21). While similar results were seen  
19 using luciferase-based ATP measures, a change in intracellular pH and Perceval intensity  
20 cannot be excluded.

21       In summary, we have identified a novel mechanism by which glucocorticoids  
22 maintain beta cell function in rodent and human beta cells through engagement of parallel  
23 cAMP pathways. Failure of this protective feedback loop may contribute to impaired insulin  
24 release during states of glucocorticoid excess (e.g. Cushing's syndrome).

25

## 1 AUTHOR CONTRIBUTIONS

2 N.H.F.F. conceived and devised the study, performed the experiments and analysed data.  
3 C.L.D., Y.S.E., N.V. and D.A.J. performed experiments and analyzed data. G.A.R. provided  
4 reagents. G.G.L. provided reagents and analyzed data. M.P., M.B., L.P. and R.N. isolated and  
5 provided human islets. D.J.H. supervised the research, conceived and devised the study,  
6 performed analysis and wrote the manuscript with input from all authors. D.J.H. is the  
7 guarantor of this work and, as such, had full access to all the data in the study and takes  
8 responsibility for the integrity of the data and the accuracy of the data analysis.

## 9 ACKNOWLEDGMENTS

10 We thank Prof. Gary Yellen (Harvard University) for providing the cDNA construct for  
11 Perceval. We thank Dr. Jocelyn E. Manning Fox and Prof. Patrick E MacDonald for  
12 provision of human islets *via* the Alberta Diabetes Institute IsletCore at the University of  
13 Alberta in Edmonton with the assistance of the Human Organ Procurement and Exchange  
14 (HOPE) program, Trillium Gift of Life Network (TGLN) and other Canadian organ  
15 procurement organizations. We are grateful to the European Consortium for Islet  
16 Transplantation (ECIT), which was supported by JDRF award 31-2008-416 (ECIT Islet for  
17 Basic Research program).

18 D.J.H. was supported by a Diabetes UK R.D. Lawrence (12/0004431) and EFSD/Novo  
19 Nordisk Rising Star Fellowships, a Wellcome Trust Institutional Support Award, and an  
20 MRC Project Grant (MR/N00275X/1). P.M. and M.B. were supported by the Innovative  
21 Medicine Initiative Joint Undertaking under grant agreement no. 155005 (IMIDIA), resources  
22 of which are composed of financial contribution from the European Union's Seventh  
23 Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution, and by  
24 the Italian Ministry of University and Research (PRIN 2010-2012). L.P. provided human

1 islets through collaboration with the Diabetes Research Institute, IRCCS San Raffaele  
2 Scientific Institute (Milan), within the European islet distribution program for basic research  
3 supported by JDRF (1-RSC-2014-90-I-X). G.A.R. was supported by Wellcome Trust Senior  
4 Investigator (WT098424AIA) and Royal Society Wolfson Research Merit Awards, and by  
5 MRC Programme (MR/J0003042/1), MRC Project (MR/N00275X/1), Biological and  
6 Biotechnology Research Council (BB/J015873/1) and Diabetes UK Project (11/0004210)  
7 grants. D.A.J. and N.V. were supported by the National Institutes of Health grant  
8 R01DK097392, and ADA grant 1-17-IBS-024. G.G.L. was supported by a Wellcome Trust  
9 Senior Research Fellowship (104612/Z/14/Z). This project has received funding from the  
10 European Research Council (ERC) under the European Union's Horizon 2020 research and  
11 innovation programme (Starting Grant 715884 to D.J.H.).

## 12 **CONFLICT OF INTEREST**

13 The authors have declared that no conflict of interest exists.

## 1 REFERENCES

- 2 1. Andrews RC, Walker BR: Glucocorticoids and insulin resistance: old hormones, new  
3 targets. Clin Sci 1999;96:513-523
- 4 2. Seckl JR, Walker BR: Minireview: 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1— A  
5 Tissue-Specific Amplifier of Glucocorticoid Action1. Endocrinology 2001;142:1371-1376
- 6 3. Ogawa A, Johnson JH, Ohneda M, McAllister CT, Inman L, Alam T, Unger RH: Roles of  
7 insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. J Clin Invest  
8 1992;90:497-504
- 9 4. Delaunay F, Khan A, Cintra A, Davani B, Ling ZC, Andersson A, Ostenson CG,  
10 Gustafsson J, Efendic S, Okret S: Pancreatic beta cells are important targets for the  
11 diabetogenic effects of glucocorticoids. J Clin Invest 1997;100:2094-2098
- 12 5. Lambillotte C, Gilon P, Henquin JC: Direct glucocorticoid inhibition of insulin secretion.  
13 An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997;99:414-423
- 14 6. Davani B, Khan A, Hult M, Martensson E, Okret S, Efendic S, Jornvall H, Oppermann  
15 UCT: Type 1 11 -Hydroxysteroid Dehydrogenase Mediates Glucocorticoid Activation and  
16 Insulin Release in Pancreatic Islets. J Biol Chem 2000;275:34841-34844
- 17 7. Swali A, Walker EA, Lavery GG, Tomlinson JW, Stewart PM: 11 $\beta$ -Hydroxysteroid  
18 dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets.  
19 Diabetologia 2008;51:2003-2011
- 20 8. Koizumi M, Yada T: Sub-chronic stimulation of glucocorticoid receptor impairs and  
21 mineralocorticoid receptor protects cytosolic Ca<sup>2+</sup> responses to glucose in pancreatic  $\beta$ -cells.  
22 J Endocrinol 2008;197:221-229
- 23 9. Gremlich S, Roduit R, Thorens B: Dexamethasone Induces Posttranslational Degradation  
24 of GLUT2 and Inhibition of Insulin Secretion in Isolated Pancreatic Cells: Comparison with  
25 the Effects of Fatty Acids. J Biol Chem 1997;272:3216-3222

- 1 10. Ortsäter H, Alberts P, Warpman U, Engblom LOM, Abrahmsén L, Bergsten P:  
2 Regulation of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 and glucose-stimulated insulin  
3 secretion in pancreatic islets of Langerhans. *Diabetes Metab Res Rev* 2005;21:359-366
- 4 11. Turban S, Liu X, Ramage L, Webster SP, Walker BR, Dunbar DR, Mullins JJ, Seckl JR,  
5 Morton NM: Optimal elevation of beta-cell 11 $\beta$ -hydroxysteroid dehydrogenase type 1 is a  
6 compensatory mechanism that prevents high-fat diet-induced beta-cell failure. *Diabetes*  
7 2012;61:642-652
- 8 12. Rafacho A, Marroquí L, Taboga SR, Abrantes JLF, Silveira LR, Boschero AC, Carneiro  
9 EM, Bosqueiro JR, Nadal A, Quesada I: Glucocorticoids in Vivo Induce Both Insulin  
10 Hypersecretion and Enhanced Glucose Sensitivity of Stimulus-Secretion Coupling in Isolated  
11 Rat Islets. *Endocrinology* 2010;151:85-95
- 12 13. Stamateris RE, Sharma RB, Hollern DA, Alonso LC: Adaptive beta-cell proliferation  
13 increases early in high-fat feeding in mice, concurrent with metabolic changes, with induction  
14 of islet cyclin D2 expression. *Am J Physiol Endocrinol Metab* 2013;305:E149-159
- 15 14. Gesina E, Tronche F, Herrera P, Duchene B, Tales W, Czernichow P, Breant B:  
16 Dissecting the role of glucocorticoids on pancreas development. *Diabetes* 2004;53:2322-2329
- 17 15. Shen CN, Seckl JR, Slack JM, Tosh D: Glucocorticoids suppress beta-cell development  
18 and induce hepatic metaplasia in embryonic pancreas. *Biochem J* 2003;375:41-50
- 19 16. Guo S, Dai C, Guo M, Taylor B, Harmon JS, Sander M, Robertson RP, Powers AC, Stein  
20 R: Inactivation of specific beta cell transcription factors in type 2 diabetes. *J Clin Invest*  
21 2013;123:3305-3316
- 22 17. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmolle D, Jamieson P, Best R,  
23 Brown R, Edwards CR, Seckl JR, Mullins JJ: 11 $\beta$ -hydroxysteroid dehydrogenase type 1  
24 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia  
25 on obesity or stress. *Proc Natl Acad Sci U S A* 1997;94:14924-14929

- 1 18. Lyon J, Manning Fox JE, Spigelman AF, Kim R, Smith N, O'Gorman D, Kin T, Shapiro  
2 AM, Rajotte RV, MacDonald PE: Research-Focused Isolation of Human Islets From Donors  
3 With and Without Diabetes at the Alberta Diabetes Institute IsletCore. *Endocrinology*  
4 2016;157:560-569
- 5 19. Hodson DJ, Tarasov AI, Gimeno Brias S, Mitchell RK, Johnston NR, Haghollahi S, Cane  
6 MC, Bugliani M, Marchetti P, Bosco D, Johnson PR, Hughes SJ, Rutter GA: Incretin-  
7 modulated beta cell energetics in intact islets of Langerhans. *Mol Endocrinol* 2014;28:860-  
8 871
- 9 20. Hodson DJ, Mitchell RK, Marselli L, Pullen TJ, Gimeno Brias S, Semplici F, Everett KL,  
10 Cooper DM, Bugliani M, Marchetti P, Lavallard V, Bosco D, Piemonti L, Johnson PR,  
11 Hughes SJ, Li D, Li WH, Shapiro AM, Rutter GA: ADCY5 couples glucose to insulin  
12 secretion in human islets. *Diabetes* 2014;63:3009-3021
- 13 21. Li J, Shuai HY, Gylfe E, Tengholm A: Oscillations of sub-membrane ATP in glucose-  
14 stimulated beta cells depend on negative feedback from Ca(2+). *Diabetologia* 2013;56:1577-  
15 1586
- 16 22. Zhu L, Almaca J, Dadi PK, Hong H, Sakamoto W, Rossi M, Lee RJ, Vierra NC, Lu H,  
17 Cui Y, McMillin SM, Perry NA, Gurevich VV, Lee A, Kuo B, Leapman RD, Matschinsky  
18 FM, Doliba NM, Urs NM, Caron MG, Jacobson DA, Caicedo A, Wess J: beta-arrestin-2 is an  
19 essential regulator of pancreatic beta-cell function under physiological and  
20 pathophysiological conditions. *Nat Commun* 2017;8:14295
- 21 23. Hodson DJ, Mitchell RK, Bellomo EA, Sun G, Vinet L, Meda P, Li D, Li WH, Bugliani  
22 M, Marchetti P, Bosco D, Piemonti L, Johnson P, Hughes SJ, Rutter GA: Lipotoxicity  
23 disrupts incretin-regulated human beta cell connectivity. *J Clin Invest* 2013;123:4182-4194



- 1    24. Hatlapatka K, Willenborg M, Rustenbeck I: Plasma membrane depolarization as a  
2    determinant of the first phase of insulin secretion. *Am J Physiol Endocrinol Metab*  
3    2009;297:E315-322
- 4    25. Piccand J, Strasser P, Hodson David J, Meunier A, Ye T, Keime C, Birling M-C, Rutter  
5    Guy A, Gradwohl G: Rfx6 Maintains the Functional Identity of Adult Pancreatic  $\beta$  Cells. *Cell*  
6    Reports 2014;
- 7    26. Berg J, Hung YP, Yellen G: A genetically encoded fluorescent reporter of ATP:ADP  
8    ratio. *Nat Methods* 2009;6:161-166
- 9    27. Rutter GA, Pullen TJ, Hodson DJ, Martinez-Sanchez A: Pancreatic beta-cell identity,  
10    glucose sensing and the control of insulin secretion. *Biochem J* 2015;466:203-218
- 11    28. Holz GG, Kang G, Harbeck M, Roe MW, Chepurny OG: Cell physiology of cAMP  
12    sensor Epac. *J Physiol* 2006;577:5-15
- 13    29. Tian G, Sol ER, Xu Y, Shuai H, Tengholm A: Impaired cAMP generation contributes to  
14    defective glucose-stimulated insulin secretion after long-term exposure to palmitate. *Diabetes*  
15    2015;64:904-915
- 16    30. Morgan SA, McCabe EL, Gathercole LL, Hassan-Smith ZK, Lerner DP, Bujalska IJ,  
17    Stewart PM, Tomlinson JW, Lavery GG: 11 $\beta$ -HSD1 is the major regulator of the tissue-  
18    specific effects of circulating glucocorticoid excess. *Proc Natl Acad Sci U S A*  
19    2014;111:E2482-2491
- 20    31. Tomlinson JW, Moore JS, Clark PM, Holder G, Shakespeare L, Stewart PM: Weight loss  
21    increases 11 $\beta$ -hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. *J*  
22    *Clin Endocrinol Metab* 2004;89:2711-2716
- 23    32. Liu YJ, Grapengiesser E, Gylfe E, Hellman B: Crosstalk between the cAMP and inositol  
24    trisphosphate-signalling pathways in pancreatic beta-cells. *Arch Biochem Biophys*  
25    1996;334:295-302

- 1 33. Jacobson DA, Mendez F, Thompson M, Torres J, Cochet O, Philipson LH: Calcium-  
2 activated and voltage-gated potassium channels of the pancreatic islet impart distinct and  
3 complementary roles during secretagogue induced electrical responses. *J Physiol*  
4 2010;588:3525-3537
- 5 34. Henquin JC: Triggering and amplifying pathways of regulation of insulin secretion by  
6 glucose. *Diabetes* 2000;49:1751-1760
- 7 35. Ammala C, Ashcroft FM, Rorsman P: Calcium-independent potentiation of insulin  
8 release by cyclic AMP in single beta-cells. *Nature* 1993;363:356-358
- 9 36. Pullen TJ, Huising MO, Rutter GA: Analysis of Purified Pancreatic Islet Beta and Alpha  
10 Cell Transcriptomes Reveals 11 $\beta$ -Hydroxysteroid Dehydrogenase (Hsd11b1) as a Novel  
11 Disallowed Gene. *Frontiers in Genetics* 2017;08
- 12 37. Segerstolpe Å, Palasantza A, Eliasson P, Andersson E-M, Andréasson A-C, Sun X,  
13 Picelli S, Sabirsh A, Clausen M, Bjursell MK, Smith David M, Kasper M, Ämmälä C,  
14 Sandberg R: Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and  
15 Type 2 Diabetes. *Cell Metab* 2016;24:593-607
- 16 38. Sun K, Chowdhury S, Grimm L, Gong YJK, Wang B, Li B, Srikant CB, Gao Z-h, Liu J-  
17 L: Decreased 11 $\beta$ -Hydroxysteroid Dehydrogenase 1 Level and Activity in Murine Pancreatic  
18 Islets Caused by Insulin-Like Growth Factor I Overexpression. *PLoS ONE*  
19 2015;10:e0136656
- 20 39. Abrahams L, Semjonous NM, Guest P, Zielinska A, Hughes B, Lavery GG, Stewart PM:  
21 Biomarkers of hypothalamic-pituitary-adrenal axis activity in mice lacking 11beta-HSD1 and  
22 H6PDH. *J Endocrinol* 2012;214:367-372
- 23 40. Shibasaki T, Takahashi H, Miki T, Sunaga Y, Matsumura K, Yamanaka M, Zhang C,  
24 Tamamoto A, Satoh T, Miyazaki J, Seino S: Essential role of Epac2/Rap1 signaling in

- 1 regulation of insulin granule dynamics by cAMP. *Proc Natl Acad Sci U S A*  
2 2007;104:19333-19338
- 3 41. Kaihara KA, Dickson LM, Jacobson DA, Tamarina N, Roe MW, Philipson LH,  
4 Wicksteed B: beta-Cell-specific protein kinase A activation enhances the efficiency of  
5 glucose control by increasing acute-phase insulin secretion. *Diabetes* 2013;62:1527-1536
- 6 42. Cooper DM: Regulation and organization of adenylyl cyclases and cAMP. *Biochem J*  
7 2003;375:517-529
- 8 43. Kitaguchi T, Oya M, Wada Y, Tsuboi T, Miyawaki A: Extracellular Calcium influx  
9 activates Adenylate Cyclase 1 and potentiates Insulin secretion in MIN6 cells. *Biochem J*  
10 2013;
- 11 44. Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M:  
12 Pathophysiology of dyslipidemia in Cushing's syndrome. *Neuroendocrinology* 2010;92 Suppl  
13 1:86-90
- 14 45. Idevall-Hagren O, Barg S, Gylfe E, Tengholm A: cAMP mediators of pulsatile insulin  
15 secretion from glucose-stimulated single beta-cells. *J Biol Chem* 2010;285:23007-23018
- 16 46. Dyachok O, Idevall-Hagren O, S  getorp J, Tian G, Wuttke A, Arri  merlou C, Akusj  rvi  
17 G, Gylfe E, Tengholm A: Glucose-Induced Cyclic AMP Oscillations Regulate Pulsatile  
18 Insulin Secretion. *Cell Metab* 2008;8:26-37
- 19 47. Landa LR, Harbeck M, Kaihara K, Chepurny O, Kitiphongspattana K, Graf O, Nikolaev  
20 VO, Lohse MJ, Holz GG, Roe MW: Interplay of Ca<sup>2+</sup> and cAMP Signaling in the Insulin-  
21 secreting MIN6 -Cell Line. *J Biol Chem* 2005;280:31294-31302
- 22 48. Tarasov AI, Griffiths EJ, Rutter GA: Regulation of ATP production by mitochondrial  
23 Ca(2+). *Cell Calcium* 2012;52:28-35

1 49. Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y: Structural basis for allosteric  
2 regulation of the monomeric allosteric enzyme human glucokinase. *Structure* 2004;12:429-  
3 438

4 50. Detimary P, Gilon P, Nenquin M, Henquin JC: Two sites of glucose control of insulin  
5 release with distinct dependence on the energy state in pancreatic B-cells. *Biochem J*  
6 1994;297 ( Pt 3):455-461

7

1 **FIG.S AND LEGENDS**

2 **Figure 1** - Glucocorticoids suppress cytosolic  $\text{Ca}^{2+}$  fluxes in response to glucose and glucose  
3 + KCl. *A*: Mean  $\pm$  S.E.M intensity-over-time traces showing glucose- and glucose + KCl-  
4 stimulated  $\text{Ca}^{2+}$  rises in mouse islets treated for 48 hrs with 11-DHC or corticosterone ( $n =$   
5 14-28 islets from 6 animals). *B*: Representative max intensity projection images showing  
6 impaired  $\text{Ca}^{2+}$  signaling in glucose-stimulated control (Con)-, 11-DHC 200 nM-, and  
7 corticosterone (Cort)-treated islets (scale bar, 20  $\mu\text{m}$ ) (images cropped to show a single islet).  
8 *C*: Summary bar graph showing a significant reduction in the amplitude of glucose-  
9 stimulated  $\text{Ca}^{2+}$  rises following treatment with either glucocorticoid ( $n = 14-28$  islets from 6  
10 animals). *D*: As for *C*, but area-under-the-curve (AUC). *E*: As for *C* but glucose + KCl. *F*:  
11 Corticosterone and 11-DHC significantly decrease  $\text{Ca}^{2+}$  spiking frequency at high glucose  
12 (representative traces shown) ( $n = 14$  islets from 3 animals). *G*: As for *F*, but summary bar  
13 graph showing  $\text{Ca}^{2+}$  oscillations per min. *H*. Cortisone and cortisol blunt glucose- and  
14 glucose + KCl-stimulated  $\text{Ca}^{2+}$  rises in human islets (representative traces shown) ( $n = 15-18$   
15 islets from 3 donors, 48 hrs). *I* and *J*: As for *H*, but summary bar graphs showing amplitude  
16 of  $\text{Ca}^{2+}$  responses to glucose (*I*) and glucose + KCl (*J*). *K*: 11-DHC and corticosterone do not  
17 affect  $\text{Ca}^{2+}$  responses to the incretin-mimetic, exendin 4 (Ex4) 10 nM (representative traces  
18 shown) ( $n = 14-17$  islets from 3 animals). *L* and *M*: As for *K*, but summary bar graphs  
19 showing oscillation frequency (*L*) and AUC (*M*). G3 = 3 mM glucose; G11 = 11 mM  
20 glucose; G17 = 17 mM glucose. KCl was applied at 10 mM. \* $P < 0.05$ , \*\* $P < 0.01$  and NS,  
21 non-significant; one-way ANOVA (Bonferroni's post hoc test). Corticosterone was applied at  
22 20 nM for 48 hr. Traces in *F*, *H* and *K* share the same  $F/F_{\text{min}}$  scale but are offset in the y-axis.  
23 Unless otherwise stated, data represent the mean  $\pm$  S.D.

24

**Figure 2** – Glucocorticoids impair VDCC function despite preserved beta cell identity and metabolism. *A-F*: Expression of mRNA for the beta cell maturity markers *Pdx-1* (*A-C*) and *Nkx6.1* (*D-F*) are similar in control and 11-DHC/corticosterone-treated islets ( $n = 4-7$  animals, 48 hrs). *G*: Mean  $\pm$  S.E.M traces showing no effect of glucocorticoids on maximal ATP/ADP responses to glucose, measured using the biosensor Perceval. *H*: As for *G*, but summary bar graph showing the amplitude of ATP/ADP rises ( $n = 7$  islets from 4 animals). *I*: 11-DHC and corticosterone reduce VDCC conductance, as shown by the voltage-current (I-V) relationship ( $n = 4$  animals) (\* 11-DHC *versus* control; # corticosterone *versus* control). *J*: As for *I*, but representative  $\text{Ca}^{2+}$  current traces. *K-P*: Expression levels of the VDCC  $\alpha/\beta$  subunits *Cacna1c* (*K* and *L*), *Cacnb2* (*M* and *N*) and *Cacna1d* (*O* and *P*) are not significantly altered by 11-DHC or corticosterone ( $n = 4-6$  animals, 48 hrs). G3 = 3 mM glucose; G17 = 17 mM glucose. #/\*P<0.05, ###/\*\*P<0.01 and NS, non-significant; Student's t-test, Student's paired t-test or one-way ANOVA (Bonferroni's post hoc test). Corticosterone was applied at 20 nM for 48 hr. Unless otherwise stated, data represent the mean  $\pm$  S.D.

15

**Figure 3** - Insulin secretion from islets is maintained in the face of excess glucocorticoid. *A*: Basal, glucose-stimulated and glucose + KCl-stimulated insulin secretion is unaffected following 48 hr treatment of mouse islets with either 11-DHC or corticosterone ( $n = 5$  animals). *B-D*: QRT-PCR analyses of *Ins1* mRNA expression shows no significant changes in response to 11-DHC 20 nM (*B*), 11-DHC 200 nM (*C*) or corticosterone (*D*) exposure ( $n = 4-7$  animals). *E*: Total insulin content is unaffected by exposure to 11-DHC or corticosterone ( $n = 3$  animals). *F*: Basal, glucose-stimulated and glucose + KCl-stimulated insulin secretion is unaffected following 48 hr treatment of human islets with either cortisone 200 nM or cortisol 20 nM ( $n = 3$  donors). *G*: As for *F*, but stimulation index to better account for differences in basal secretion between islet batches from the different isolation centres.

1 \*P<0.05, \*\*P<0.01 and NS, non-significant; Student's t-test, one-way ANOVA (Bonferroni's  
 2 post hoc test) or two-way ANOVA. G3 = 3 mM glucose; G17 = 17 mM glucose.  
 3 Corticosterone was applied at 20 nM for 48 hr. KCl was applied at 10 mM. Unless otherwise  
 4 stated, data represent the mean  $\pm$  S.D or range.

5

6 **Figure 4** - Glucocorticoids potentiate cAMP signaling. *A*: Both 11-DHC and corticosterone  
 7 (Cort) amplify glucose-stimulated cAMP generation, as measured online using the biosensor  
 8 Epac2-camps (FSK, forskolin; positive control) (mean  $\pm$  S.E.M traces shown) ( $n$  = 20-24  
 9 islets from 5 animals). *B*: Summary bar graph showing significant effects of either  
 10 glucocorticoid on the AUC of cAMP responses to glucose. *C*: Representative images of  
 11 FRET responses in control-, 11-DHC- and corticosterone (Cort)-treated beta cells expressing  
 12 Epac2-camps (scale bar, 10  $\mu$ m). *D*: Inhibition of PKA decreases glucose-stimulated insulin  
 13 in the presence of 11-DHC but not control ( $n$  = 3 animals) (mean and range shown). *E*: 11-  
 14 DHC and corticosterone (Cort) increase the fraction of the cell membrane occupied by insulin  
 15 granules (V/v). *F*: Representative Structured Illumination Microscopy (SIM) images showing  
 16 insulin granules in control-, 11-DHC- and corticosterone (Cort)-treated islets ( $n$  = 8 cells  
 17 from 3 animals) (scale bar = 5  $\mu$ m) (lower panel shows zoom-in). *G*: Cortisone and cortisol  
 18 augment glucose-stimulated cAMP generation in human islets (mean  $\pm$  S.E.M traces shown).  
 19 *H*: Summary bar graph showing significant effects of cortisone and cortisol on the AUC of  
 20 cAMP responses to glucose ( $n$  = 10-11 islets from 3 donors). *I*: Glucocorticoid does not  
 21 affect cAMP responses to exendin-4 (Ex4) 10 nM ( $n$  = 24-46 islets from 4 animals). *J*: As for  
 22 *I*, but summary bar graph showing AUC of cAMP responses. *K* and *L*: Relative (fold-change)  
 23 expression levels of *Adcy1*, 5, 6, 8 and 9 in 11-DHC (*K*) and corticosterone (*L*)-treated islets  
 24 ( $n$  = 4-5 animals). *M*: Palmitate but not BSA control prevents 11-DHC from augmenting  
 25 cAMP responses to glucose (Palm, palmitate) ( $n$  = 23-27 islets from 4 animals) (traces

represent mean  $\pm$  S.E.M). *N*. As for *M*, but summary bar graph showing AUC of cAMP responses. G3 = 3 mM glucose; G11 = 11 mM glucose; G17 = 17 mM glucose. \* $P < 0.05$ , \*\* $P < 0.01$  and NS, non-significant; Student's t-test or one-way ANOVA (with Bonferroni's or Tukey's post hoc test). 11-DHC and corticosterone were applied for 48 hr at 200 nM and 20 nM, respectively. Unless otherwise stated, data represent the mean  $\pm$  S.D.

**Figure 5** - Deletion of *Hsd11b1* reverses the effects of glucocorticoids on  $\text{Ca}^{2+}$  signaling. *A*: Mean intensity-over-time traces showing a reduction in glucose- and glucose + KCl-stimulated  $\text{Ca}^{2+}$  rises in *Hsd11b1*<sup>+/-</sup> islets treated for 48 hrs with 11-DHC or corticosterone (Cort) ( $n = 15-19$  islets from 3 animals). *B* and *C*: As for *A*, but summary bar graphs showing the amplitude of  $\text{Ca}^{2+}$  responses to glucose (*B*) and glucose + KCl (*C*). *D*: Representative max intensity projection images showing impaired glucose-stimulated  $\text{Ca}^{2+}$  rises in 11-DHC- and corticosterone- compared to control (Con)-treated *Hsd11b1*<sup>+/-</sup> islets (scale bar, 20  $\mu\text{m}$ ) (images cropped to show a single islet). *E*: Mean  $\pm$  S.E.M intensity-over-time traces showing intact glucose- and glucose + KCl-stimulated  $\text{Ca}^{2+}$  rises in *Hsd11b1*<sup>-/-</sup> islets treated for 48 hrs with 11-DHC or corticosterone ( $n = 19-28$  islets from 3 animals). *F* and *G*: As for *E*, but summary bar graphs showing the amplitude of  $\text{Ca}^{2+}$  responses to glucose (*F*) and glucose + KCl (*G*). *H*: Representative max intensity projection images showing similar glucose-stimulated  $\text{Ca}^{2+}$  rises in 11-DHC- and corticosterone- compared to control (Con)-treated *Hsd11b1*<sup>-/-</sup> islets (scale bar, 20  $\mu\text{m}$ ) (images cropped to show a single islet). G3 = 3 mM glucose; G17 = 17 mM glucose. \* $P < 0.05$ , \*\* $P < 0.01$  and NS, non-significant, one-way ANOVA (Bonferroni's post hoc test). 11-DHC and corticosterone were applied for 48 hr at 200 nM and 20 nM, respectively. KCl was applied at 10 mM. Unless otherwise stated, data represent the mean  $\pm$  S.D.



**Figure 6** - Deletion of *Hsd11b1* reverses the effects of 11-DHC on cAMP signaling. *A*: Mean  $\pm$  S.E.M intensity-over-time traces showing cAMP responses to glucose in 11-DHC- and corticosterone (Cort)-treated *Hsd11b1*<sup>+/-</sup> islets (FSK, forskolin; positive control) (*n* = 15-19 islets from 3 animals). *B* and *C*: As for *A*, but summary bar graphs showing the amplitude (*B*) and AUC (*C*) of cAMP responses. *D*: Representative images of cAMP responses to glucose in control (Con)-, 11-DHC- or corticosterone-treated *Hsd11b1*<sup>+/-</sup> islets expressing Epac2-camps (scale bar, 10  $\mu$ m). *E*: Mean  $\pm$  S.E.M intensity-over-time traces showing that cAMP responses to glucose are potentiated by 11-DHC, but not corticosterone, in *Hsd11b1*<sup>-/-</sup> islets (*n* = 22-23 islets from 3 animals). *F* and *G*: As for *E*, but summary bar graphs showing the amplitude (*F*) and AUC (*G*) of cAMP responses. *H*: Representative images of cAMP responses to glucose in control (Con)-, 11-DHC- and corticosterone-treated *Hsd11b1*<sup>-/-</sup> islets expressing Epac2-camps (scale bar, 10  $\mu$ m). *I*: Insulin secretion in response to glucose is significantly improved in corticosterone- compared to control and 11-DHC-treated *Hsd11b1*<sup>-/-</sup> islets (*n* = 4 animals). *J* and *K*: Relative (fold-change) expression levels of *Adcy1*, 5, 6, 8 and 9 in 11-DHC (*J*) and corticosterone (*K*)-treated *Hsd11b1*<sup>-/-</sup> islets (*n* = 5 animals). G3 = 3 mM glucose; G17 = 17 mM glucose. \**P*<0.05, \*\**P*<0.01 and NS, non-significant, Student's t-test or one-way ANOVA (Bonferroni's post hoc test). 11-DHC and corticosterone were applied for 48 hr at 200 nM and 20 nM, respectively. KCl was applied at 10 mM. Unless otherwise stated, data represent the mean  $\pm$  S.D.

20

**Figure 7** - 11-DHC effects are mediated through the glucocorticoid receptor. *A*: The glucocorticoid receptor antagonist RU486 prevents the suppressive effects of 11-DHC on glucose- and glucose + KCl-stimulated Ca<sup>2+</sup> signals (mean  $\pm$  S.E.M traces shown) (*n* = 12-13 islets from 4 animals). *B* and *C*: As for, *A* but summary bar graphs showing that 11-DHC does not affect Ca<sup>2+</sup> responses to glucose (*B*) or glucose + KCl (*C*) in RU486-treated islets.

*D*: Representative max intensity projection images showing impaired  $\text{Ca}^{2+}$  rises in 11-DHC-treated islets, which can be reversed using the glucocorticoid receptor antagonist RU486 (scale bar, 20  $\mu\text{m}$ ) (images cropped to show a single islet). *E*: RU486 blocks the effects of corticosterone (Cort) on  $\text{Ca}^{2+}$  responses to glucose ( $n = 14-17$  islets from 6 animals). *F*: As for *E*, but RU486 is unable to significantly affect  $\text{Ca}^{2+}$  responses to glucose + KCl in corticosterone-treated islets ( $n = 14-17$  islets from 6 animals). \* $P < 0.05$ , \*\* $P < 0.01$  and NS, non-significant, one-way ANOVA (Bonferroni's post hoc test). 11-DHC and corticosterone were applied for 48 hr at 200 nM and 20 nM, respectively. KCl was applied at 10 mM. Unless otherwise stated, data represent the mean  $\pm$  S.D.

**Figure 8** - Glucocorticoids impair  $\text{K}_{\text{ATP}}$ -independent signals to reduce ionic fluxes in glucose-stimulated beta cells. This is further exacerbated by Hsd11b1, which increases availability of more active glucocorticoid (11-DHC/cortisone  $\rightarrow$  corticosterone/cortisol) in a paracrine manner. However, insulin secretion is preserved, since glucocorticoids are able to reprogram the beta cell signaling cassette towards a cAMP phenotype, most likely through upregulation of specific Adcy isoforms.





Figure 2



## Diabetes




Figure 4




Figure 5






Figure 6








Figure 7 Diabetes





**SUPPLEMENTAL INFORMATION**

**Supplemental Figure 1** - Delta  $\text{Ca}^{2+}$  rises in response to glucose and KCl at high glucose in glucocorticoid-treated islets.

**Supplemental Figure 2** - Glucocorticoids impair  $\text{Ca}^{2+}$  responses to glucose and KCl at high glucose as measured using Fura2.

**Supplemental Figure 3** - Glucocorticoids do not influence the time to onset or amplitude of ATP/ADP responses to glucose.

**Supplemental Figure 4** - Glucocorticoids do not affect glucose-stimulated ATP production

**Supplemental Figure 5** - *Hsd11b1* and *HSD11B1* mRNA expression in mouse and human tissue.

**Supplemental Figure 6** -11-DHC suppresses delta  $\text{Ca}^{2+}$  rises in *Hsd11b1*<sup>+/-</sup> but not *Hsd11b1*<sup>-/-</sup> islets.

**Supplemental Figure 7** -11-DHC augments delta cAMP rises in *Hsd11b1*<sup>+/-</sup> but not *Hsd11b1*<sup>-/-</sup> islets.

**Supplemental Figure 8** - R486 blocks the effects of glucocorticoids on  $\text{Ca}^{2+}$  rises.


**Supplemental Table 1** - Human islet donor characteristics.

**Supplemental Table 2** – Epac2-camps single and dual channel fluorescence under maximal stimulation in mouse islets


**Supplemental Table 3** - Primer sequences.

**Supplemental Table 4** – Basal intracellular  $\text{Ca}^{2+}$  concentration in human islets.


**Supplemental Table 5** – Effect of KCl concentration on amplitude  $\text{Ca}^{2+}$  responses at 3 mM glucose.




**Supplemental Figure 1** - Delta  $\text{Ca}^{2+}$  rises in response to glucose and KCl at high glucose in glucocorticoid-treated islets. *A*: Glucocorticoids significantly impair the amplitude of  $\text{Ca}^{2+}$  responses to glucose. *B*: As for *A*, but  $\text{Ca}^{2+}$  responses to 10 mM KCl (amplitude measured *versus* 17 mM glucose; G17). \* $P < 0.05$ , \*\* $P < 0.01$  and NS, non-significant; one-way ANOVA (Bonferroni's post hoc test). 11-DHC and corticosterone were applied at 200 nM or 20 nM, respectively. Data represent the mean  $\pm$  S.D. N numbers as for Figure 1.



**Supplemental Figure 2** - Glucocorticoids impair  $\text{Ca}^{2+}$  responses to glucose and KCl at high glucose as measured using Fura2. *A*: Ratiometric Fura2 recordings showing glucose- and glucose + 10 mM KCl-stimulated  $\text{Ca}^{2+}$  rises in mouse islets treated for 48 hrs with 11-DHC or corticosterone (mean  $\pm$  S.E.M intensity-over-time traces shown) ( $n = 16-17$  islets from 4 animals). *B-C*: Summary bar graphs showing a significant reduction in the amplitude of glucose- (*B*) and 10 mM KCl- (*C*) stimulated  $\text{Ca}^{2+}$  rises following treatment with either glucocorticoid (KCl amplitude measured *versus* 17 mM glucose; G17). *D*: Peak  $\text{Ca}^{2+}$  responses to 10 mM KCl at low (3 mM) glucose are not affected or significantly increased by 11-DHC or corticosterone exposure, respectively. Sustained  $\text{Ca}^{2+}$  responses to 10 mM KCl at low (3 mM) glucose are significantly increased by both glucocorticoids. *E*: As for *D*, but summary bar graph (peak  $\text{Ca}^{2+}$  responses, left panel; sustained  $\text{Ca}^{2+}$  responses, right panel) ( $n = 7-9$  islets from 2 animals). *F*: Peak and sustained  $\text{Ca}^{2+}$  responses to 30 mM KCl at low (3 mM) glucose are significantly reduced by treatment with 11-DHC or corticosterone ( $n = 31-35$  islets from 9 animals). *G*: As for *F*, but summary bar graph (peak  $\text{Ca}^{2+}$  responses, left panel; sustained  $\text{Ca}^{2+}$  responses, right panel) ( $n = 31-35$  islets from 9 animals). *H*: Glucocorticoid does not significantly alter the Fura2 340/385 ratio ( $n = 8-10$  islets from 3 animals). G3 = 3 mM glucose; G17 = 17 mM glucose. \*\* $P < 0.01$  and NS, non-significant; one-way ANOVA (Bonferroni's posthoc test). 11-DHC and corticosterone were applied for 48 hrs at 200 nM or 20 nM, respectively. Unless otherwise stated, data represent the mean  $\pm$  S.D.




**Supplemental Figure 3** - Glucocorticoids do not influence the time to onset or amplitude of ATP/ADP responses to glucose. *A*: Bar graph showing no effect of 11-DHC or corticosterone (Cort) on the time to the initial decrease in ATP/ADP. *B*: As for, A but amplitude of the decrease. 11-DHC and corticosterone were applied for 48 hrs at 200 nM or 20 nM, respectively. NS, non-significant; one-way ANOVA (Bonferroni's posthoc test). Data represent the mean  $\pm$  S.D.




**Supplemental Figure 4** - Glucocorticoids do not affect glucose-stimulated ATP production. High (17 mM) glucose concentration significantly increases ATP levels under all conditions examined. No differences were detected between control-, 11-DHC- and corticosterone-treated islets ( $n = 12$  animals). 11-DHC and corticosterone were applied for 48 hrs at 200 nM or 20 nM, respectively. \* $P < 0.05$ , \*\* $P < 0.01$ ; Student's  $t$ -test. NS, non-significant; one-way ANOVA. Data represent the mean and range.






**Supplemental Figure 5 - *Hsd11b1* and *HSD11B1* mRNA expression in mouse and human tissue.** *A*: Relative *Hsd11b1* gene expression in muscle, liver and islets in mice ( $n = 5$  animals). *B*: *Hsd11b1* is expressed in islets from *Hsd11b1*<sup>+/+</sup> and *Hsd11b1*<sup>+/-</sup> mice, but not *Hsd11b1*<sup>-/-</sup> animals ( $n = 3-4$  animals). *C*: *HSD11B1* levels in human islets are only an order of magnitude lower than in subcutaneous (SC) and omental (OM) fat ( $n = 4-5$  donors). Data represent the mean ± S.D.




**Supplemental Figure 6** -11-DHC suppresses  $\Delta \text{Ca}^{2+}$  rises in *Hsd11b1*<sup>+/+</sup> but not *Hsd11b1*<sup>-/-</sup> islets.

*A*: Both 11-DHC and corticosterone significantly impair the amplitude of  $\text{Ca}^{2+}$  responses to glucose in *Hsd11b1*<sup>+/+</sup> islets. *B*: As for *A*, but 10 mM KCl (amplitude measured *versus* 17 mM glucose; G17). *C*: Deletion of *Hsd11b1* (*Hsd11b1*<sup>-/-</sup>) restores  $\text{Ca}^{2+}$  responses to glucose. *D*: As for *A*, but 10 mM KCl (amplitude measured *versus* 17 mM glucose; G17). Data represent the mean  $\pm$  S.D. \* $P < 0.05$ , \*\* $P < 0.01$  and NS, non-significant; one-way ANOVA (Bonferroni's post hoc test). 11-DHC and corticosterone were applied for 48 hrs at 200 nM or 20 nM, respectively. Data represent the mean  $\pm$  S.D. N numbers as for Figure 5.



**Supplemental Figure 7** - 11-DHC augments delta cAMP rises in *Hsd11b1*<sup>+/-</sup> but not *Hsd11b1*<sup>-/-</sup> islets. *A*: Both 11-DHC and corticosterone potentiate cAMP responses to glucose in *Hsd11b1*<sup>+/-</sup> islets. *B*: Only corticosterone potentiates cAMP responses to glucose in *Hsd11b1*<sup>-/-</sup> islets. \*P<0.05, \*\*P<0.01 and NS, non-significant; one-way ANOVA (Bonferroni's post hoc test). 11-DHC and corticosterone were applied for 48 hrs at 200 nM or 20 nM, respectively. Data represent the mean  $\pm$  S.D. N numbers as for Figure 6.



**Supplemental Figure 8** - RU486 blocks the effects of glucocorticoids on Ca<sup>2+</sup> rises. *A*: RU486 prevents 11-DHC from impairing Ca<sup>2+</sup> responses to glucose. *B*: As for *A*, but 10 mM KCl (amplitude measured *versus* 17 mM glucose; G17). *C*: RU486 prevents corticosterone (Cort) from impairing Ca<sup>2+</sup> responses to glucose. *D*: As for *C*, but 10 mM KCl (amplitude measured *versus* G17). \*P<0.05, \*\*P<0.01 and NS, non-significant; one-way ANOVA (Bonferroni's post hoc test). 11-DHC and corticosterone were applied for 48 hrs at 200 nM or 20 nM, respectively. Data represent the mean ± S.D. N numbers as for Figure 7.

Age	Gender	BMI	Source
55	F	26	Milan
49	F	23.9	Milan
73	F	28.4	Alberta
71	F	35.5	Alberta
54	M	26.5	Milan
57	F	26	Milan
64	M	24.5	Pisa
44	M	34.4	Alberta

Supplemental Table 1 - Human islet donor characteristics.

Treatment	YFP intensity $\pm$ SD (AU)	CFP/YFP $\pm$ SD
Control	$2.3 \times 10^4 \pm 6.7 \times 10^3$	$1.08 \pm 0.03$
11-DHC	$2.4 \times 10^4 \pm 8.8 \times 10^3$ NS	$1.08 \pm 0.05$ NS
Corticosterone	$2.7 \times 10^4 \pm 5.0 \times 10^3$ NS	$1.07 \pm 0.04$ NS

Supplemental Table 2 – Epac2-camps single and dual channel fluorescence in mouse islets during maximal stimulation with forskolin. NS, non-significant *versus* control, one-way ANOVA (Bonferroni’s post hoc test).

Gene	Forward	Reverse
<i>Ins1</i>	GCTGGTGGGCATCCAGTAA	AATGACCTGCTTGCTGATGGT
<i>Pdx-1</i>	CCAAAGCTCACGCGTGGA	TGTTTTCTCGGGTTCCG
<i>Nkx6.1</i>	GCCTGTACCCCCCATCAAG	GTGGGTCTGGTGTGTTTTCTCTT
<i>Cacna1d</i>	GAAGCTGCTTGACCAAGTTGT	AACTTCCCCACGGTTACCTC
<i>Cacna1c</i>	CCAACCTCATCCTCTTCTTCA	ACATAGTCTGCATTGCCTAGGAT
<i>Cacnb2</i>	GCAGGAGAGCCAGATGGA	TCCTGGCTCCTTTCCATAG
<i>Adcy1</i>	CGGAATTGCATGCCTTGAA	TCCATTCTTTTGTGCATGCTACAT
<i>Adcy5</i>	CTTCACCAGCCCCAAGAAAC	GAAGCGGCAGAGCACAGAAC
<i>Adcy6</i>	AGCCTTGGATAGGAAGGGACTACT	CTCCCTGCTTTGGCTTATATACCT
<i>Adcy8</i>	TTGGGCTTCCTACACCTTGA	CGGTAGCTGTATCCTCCATTGAG
<i>Adcy9</i>	CATACAGAAGGCACCGATAG	CCGAACAGGTCATTGAGTAG
$\beta$ -actin	CGAGTCGCGTCCACCC	CATCCATGGCGAACTGGTG

Supplemental Table 3 - Primer sequences

Treatment	Ca <sup>2+</sup> concentration $\pm$ SD (nM)
Control	61.1 $\pm$ 16.2
Cortisone	60.9 $\pm$ 18.2 <sup>NS</sup>
Cortisol	52.7 $\pm$ 19.8 <sup>NS</sup>

**Supplemental Table 4** - Basal intracellular Ca<sup>2+</sup> concentration in human islets. Free Ca<sup>2+</sup> concentrations were calculated using  $K_d \cdot (F - F_{\min}) / (F_{\max} - F)$  where  $F_{\max}$  and  $F_{\min}$  represent fluorescence in the presence of 10  $\mu$ M ionomycin or 0.1% Triton + 5 mM EGTA, respectively, and  $K_d$  = 389 nM. NS, non-significant *versus* control, one-way ANOVA (Bonferroni's post hoc test).

Treatment	$\Delta$ Ca <sup>2+</sup> $\pm$ SD (340/385)
3 mM glucose + 10 mM KCl	0.76 $\pm$ 0.12
3 mM glucose + 30 mM KCl	1.85 $\pm$ 0.24**

**Supplemental Table 5** – Effect of KCl concentration on amplitude Ca<sup>2+</sup> responses at 3 mM glucose.

\*\*P<0.01 *versus* 3 mM glucose + 10 mM KCl, Student's t-test.